Eisai to Acquire Morphotek to Expand into Biologic Therapeutics
Eisai to Acquire Morphotek to Expand into Biologic Therapeutics
TOKYO, JapanEisai Co. Ltd and Eisai Corporation of North American (Woodcliff Lake, New Jersey) have signed a definitive agreement to acquire Morphotek (Exton, Pennsylvania) for $325 million. The acquisition is pending subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Morphotek develops therapeutic monoclonal antibodies and is evaluating two in early-stage clinical trials. Eisai's portfolio of oncology drugs currently includes small-molecule anticancer agents.
Articles in this issue
Curcumin Evaluated for the Treatment of Pancreatic Cancer
Tykerb Approved for Metastatic HER2+ Breast Cancer
'Male Lumpectomy' Via Focal Cryoablation Expands Treatment Options for Selected Prostate Cancer Patients
Drug for BPH May Also Reduce the Risk of Prostate Cancer
Phase III Trial of Prostvac-VF Is Launched
Electronic System Reminds Patients to Schedule Exams
Phase II Trial of Panzem for Renal Cell Carcinoma Initiated
Chemotherapy May Enrich Tumorigenic Cells in Breast Ca
Hand-Assisted Laparoscopic Technique May Reduce Surgery Time in Colon Cancer: New Study Is Underway
Watchful Waiting Management for Prostate Ca a Hard Sell
Once-Weekly SC Idraparinux Equals Standard DVT Rx
Patients Using Unapproved Cancer Agent
CT Lung Screens: No Lives Saved
Transgene Enrolls First Patients in Trial of TG 1042 in CBCL
FDA Updates Warning Labels of ESAs in Cancer Patients
Recent Videos
Related Content
